← American Pharmacists Association (APhA)
BISNonrulemakingBIS-2025-0022

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients

RIN
—
Last modified
May 29, 2025
Comment window
closed 447d ago
American Pharmacists Association (APhA) filings
1

Activity

American Pharmacists Association (APhA) filed 1 comment on this docket between May 28, 2025 and May 28, 2025. 212 other organizations filed here. The comment window closed 447d ago.

What American Pharmacists Association (APhA) filed (1)

May 28, 2025· Public Comment 113. American Pharmacists Association. Association Representative. 05/06/2025· BIS-2025-0022-0027

The American Pharmacists Association (APhA) appreciates the opportunity to provide comments to the Department of Commerce's (Department) notice of request for comments on "Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients." APhA shares the Department's belief that the quality and safety of pharmaceutical products and the global pharmaceutical supply chain are essential to national security and public health. However, APhA is concerned that broad tariffs on pharmaceuticals and their ingredients could significantly impact patient access to medications and contribute to drug shortages. APhA is the only organization advancing the entire pharmacy profession. APhA represents pharmacists, student pharmacists, and pharmacy technicians in all practice settings, including but not limited to community pharmacies, hospitals, long-term care facilities, specialty pharmacies, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and government facilities. Our members strive to improve medication use, advance patient care, and enhance public health.

View on regulations.gov →

Abstract

The Secretary of Commerce initiated an investigation to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, and critical inputs such as active pharmaceutical ingredients, and key starting materials – as well as derivative products. This investigation has been initiated under section 232 of the Trade Expansion Act of 1962, as amended. Interested parties are invited to submit written comments, data, analyses, or other information pertinent to the investigation to the Department of Commerce’s Bureau of Industry and Security. This notice identifies issues on which the Department is especially interested in obtaining the public’s views.

View on regulations.gov →

Co-filers (212)

See everyone who commented →